CDT Equity Inc. develops and repositions biopharmaceutical assets through a data-driven model that combines licensed clinical compounds, solid-form chemistry, cocrystal intellectual property and out-licensing. News about CDT commonly covers its AZD1656, AZD5658 and AZD5904 assets, patent filings, therapeutic-indication analysis, and programs spanning autoimmune disorders, idiopathic male infertility, dermatology, oncology, rare disease and animal health.
Company updates also include CDT's 20% equity interest in Sarborg Limited, whose Signature Agent, Multi-Agent and Signature Intelligence platforms are used for disease mapping and therapeutic-opportunity identification. Other recurring items include stockholder votes, Nasdaq capital-structure actions, warrants and equity financing arrangements.
CDT Equity (Nasdaq: CDT) announced a 1-for-25 reverse stock split effective March 26, 2026 at 5:00 pm ET, with shares expected to trade on a split-adjusted basis on Nasdaq at market open on March 27, 2026. As a result, every 25 issued and outstanding shares will combine into one share, reducing outstanding shares to approximately 4,722,450.
Par value remains $0.0001. Proportional adjustments apply to equity awards, convertible securities, warrants, and shares reserved under equity incentive plans. No fractional shares will be issued; cash payments will be made instead. The new CUSIP will be 20678X502.
CDT (Nasdaq: CDT) completed initial signature mapping of its asset portfolio against Sarborg's AI-curated rare disease database, identifying multiple statistically significant matches across immunology, oncology, infectious disease, paediatric and ophthalmology.
The analysis evaluated CDT assets including its solid-form patent portfolio and licensed AstraZeneca compounds AZD1656 and AZD5658 against about 1,700 rare-disease signatures. CDT plans targeted preclinical validation to build out datasets for early-stage out-licensing discussions.
CDT Equity (Nasdaq: CDT) announced stockholders approved all proposals at the Special Meeting held March 17, 2026. Key highlights include a $123M investment in Sarborg, expansion of the company IP portfolio, potential access to new capital, and a targeted annual overhead of less than $8 million.
The company says its AI-driven platform can analyze more than 3,000 diseases in hours versus conventional timelines, and CDT is shifting toward out-license deals with disease-specific partners and funds.
CDT (Nasdaq: CDT) announced a collaboration with Sarborg to map CDT’s asset portfolio, including combination therapies, against Sarborg’s expanded rare disease signature database of approximately 1,700 signatures.
CDT holds a 20% equity stake in Sarborg and intends to use the data to strengthen its IP position and explore external commercialization opportunities.
CDT (Nasdaq: CDT) notes Sarborg Limited filed a U.S. provisional patent application for its AI Signature Agent on February 12, 2026, assigned U.S. Application No. 63/981,801.
CDT holds a 20% equity stake in Sarborg and says the filing strengthens Sarborg’s IP position for its Signature Agent architecture that encodes and analyses biological, chemical and industrial signatures.
CDT (Nasdaq: CDT) announced strategic moves to expand its pharmaceutical portfolio and completed a 20% equity acquisition in Sarborg for $115 million, paid via common stock and pre-funded warrants. The company is advancing solid-form and cocrystal programs and managing licensed assets AZD1656, AZD5658 and AZD5904.
CDT says it is evaluating out-licensing, partnerships, and capital markets options to maximize asset value and enhance financial flexibility for potential transformative transactions.
CDT (Nasdaq: CDT) notes Sarborg Limited's expansion of its AI Signature Agent platform beyond pharmaceuticals into bacteria and agrochemicals. CDT holds a 20% equity stake in Sarborg. Sarborg has curated ~4,500 agrochemical and ~1,600 bacterial signatures, supporting multi‑sector scaling.
CDT says this extension broadens Sarborg's addressable markets and gives public investors exposure to its private AI signature intelligence development.
CDT (Nasdaq: CDT) agreed to acquire a 20% equity stake in Sarborg, an agentic AI signature intelligence business, for $115,000,000 settled via issuance of 598,005 new common shares and 109,978,918 pre-funded warrants, subject to shareholder approval. A further $8,000,000 deferred payment is payable upon completion of future fundraising. The deal deepens an existing collaboration focused on signature-led analysis and solid-form intellectual property, expanding CDT’s exposure beyond pharmaceuticals and aligning strategic capabilities between the companies.
CDT (Nasdaq: CDT) announced on January 2, 2026 that it has engaged NJS Foresight Bio-Advisory to identify, source and support execution of out-licensing opportunities for selected assets in its solid-form patent portfolio.
The engagement leverages NJS Foresight's >20 years of out-licensing experience and principal Dr. Nicholas J. Sarlis's clinical and pharma background. CDT's solid-form portfolio includes cocrystals and salts designed to improve solubility, bioavailability and delivery modes and carries up to 20 years of patent protection, enabling potential lifecycle extension for marketed products facing patent cliffs.
CDT said it will target licensing and royalty transactions as companies respond to patent expirations, consolidation and AI-driven adoption across biopharma.
CDT Equity (Nasdaq: CDT) on October 17, 2025 acquired 9.25648743 Bitcoin (BTC) for an aggregate purchase price of $1,005,000 (gross of fees) at an average price of $108,301.75 per BTC.
Following the purchase, CDT’s total Bitcoin holdings are 17.9090111 BTC. The company described the transaction as part of its cryptocurrency treasury reserve strategy to diversify the balance sheet and pursue long-term shareholder value through disciplined accumulation of digital assets.